Skip to main content
. Author manuscript; available in PMC: 2015 Oct 1.
Published in final edited form as: Prostaglandins Other Lipid Mediat. 2014 May 29;0:21–29. doi: 10.1016/j.prostaglandins.2014.05.002

Table 1.

Concentration of total (sum of esterified and free) and free oxylipins in plasma of healthy human subjects (n=10) at baseline (t0) and after twelve weeks (t12) of treatment with LC n-3 PUFA. Mean relative change from t0 after twelve weeks of treatment with LC n-3 PUFA was calculated individually for each subject. All results are shown as the mean ± SE. Significant differences between the two time points were determined by dependent sample t-test.

Total oxylipins Free oxylipins
concentration [nM] relative change from t0 [%] concentration [nM] relative change from t0 [%]
mean ± SE mean ± SE P (t0 vs. t12) mean ± SE mean ± SE P (t0 vs. t12)
LA-derived oxylipins Hydroxy FA 9-HODE t0 470 ± 63.4 8.50 ± 1.34
t12 347 ± 55.1 −23.6 ± 9.9 10.0 ± 0.98 10.9 ± 12.1
Epoxy FA 9(10)-EpOME t0 62.9 ± 7.60 1.56 ± 0.34
t12 37.9 ± 3.76 −33.2 ± 7.9 0.010 1.20 ± 0.27 −18.8 ± 19.4
12(13)-EpOME t0 67.2 ± 7.76 2.02 ± 0.42
t12 44.8 ± 4.87 −26.3 ± 9.3 0.026 1.98 ± 0.31 5.0 ± 19.3
Dihydroxy FA 9,10-DiHOME t0 8.35 ± 0.99 1.32 ± 0.31
t12 6.68 ± 0.68 −13.3 ± 10.3 1.40 ± 0.26 24.9 ± 33.8
12,13-DiHOME t0 6.03 ± 0.67 3.04 ± 0.71
t12 4.98 ± 0.80 −14.8 ± 9.4 3.75 ± 0.60 23.5 ± 17.6
AA-derived oxylipins Hydroxy FA 5-HETE t0 79.5 ± 7.52 0.82 ± 0.14
t12 44.6 ± 4.93 −41.3 ± 6.6 0.002 0.74 ± 0.05 −13.2 ± 9.0
8-HETE t0 68.6 ± 5.83 ≤ LOQ
t12 43.3 ± 5.71 −35.4 ± 7.7 0.004 ≤ LOQ −12.3 ± 11.0
9-HETE t0 112 ± 8.70 0.27 ± 0.05
t12 70.3 ± 9.65 −36.7 ± 7.8 0.002 0.22 ± 0.02 −11.3 ± 9.0
11-HETE t0 102 ± 8.58 0.79 ± 0.14
t12 66.4 ± 8.48 −33.6 ± 7.6 0.003 0.44 ± 0.05 −43.5 ± 11.4
12-HETE t0 100 ± 9.44 0.72 ± 0.13
t12 69.3 ± 10.1 −28.8 ± 9.4 0.021 0.40 ± 0.05 −38.3 ± 10.2
15-HETE t0 252 ± 23.8 1.09 ± 0.18
t12 139 ± 18.5 −43.6 ± 6.7 <0.001 1.04 ± 0.17 −10.0 ± 12.0
Epoxy FA 8(9)-EpETrE t0 11.5 ± 1.20 ≤ LOQ
t12 6.54 ± 0.95 −33.2 ± 15.9 0.018 ≤ LOQ
11(12)-EpETrE t0 21.0 ± 1.86 0.24 ± 0.04
t12 17.3 ± 2.23 −10.8 ± 14.1 0.20 ± 0.05 −24.2 ± 16.7
14(15)-EpETrE t0 18.4 ± 1.44 0.24 ± 0.05
t12 11.3 ± 1.16 −34.6 ± 8.1 0.005 0.22 ± 0.06 −12.2 ± 18.6
Dihydroxy FA 8,9-DiHETrE t0 4.12 ± 0.24 0.32 ± 0.05
t12 2.53 ± 0.17 −38.4 ± 3.2 <0.001 0.30 ± 0.03 −16.3 ± 6.7
11,12-DiHETrE t0 1.47 ± 0.09 0.51 ± 0.08
t12 0.89 ± 0.06 −39.1 ± 2.3 <0.001 0.43 ± 0.06 −27.2 ± 5.9
14,15-DiHETrE t0 1.01 ± 0.06 0.81 ± 0.12
t12 0.60 ± 0.05 −40.6 ± 4.2 <0.001 0.72 ± 0.06 −21.1 ± 5.8
ALA-derived oxylipins Hydroxy FA 9-HOTrE t0 5.26 ± 0.81 0.41 ± 0.07
t12 4.60 ± 0.98 −14.5 ± 7.8 0.42 ± 0.04 −1.6 ± 11.3
13-HOTrE t0 19.1 ± 2.23 0.33 ± 0.05
t12 17.1 ± 3.30 −6.3 ± 16.4 0.32 ± 0.03 −15.7 ± 7.9
Epoxy FA 9(10)-EpODE t0 2.07 ± 0.37 0.17 ± 0.04
t12 1.42 ± 0.16 −21.5 ± 9.9 0.13 ± 0.03 −16.3 ± 23.6
12(13)-EpODE t0 1.22 ± 0.24 0.11 ± 0.02
t12 0.85 ± 0.11 −15.9 ± 14.1 0.10 ± 0.02 −17.7 ± 20.8
15(16)-EpODE t0 8.65 ± 1.99 1.74 ± 0.41
t12 4.45 ± 0.69 −33.3 ± 15.6 0.041 0.92 ± 0.05 −33.7 ± 11.7
Dihydroxy FA 9,10-DiHODE t0 0.50 ± 0.04 0.11 ± 0.03
t12 0.40 ± 0.02 −12.4 ± 6.0 0.024 0.10 ± 0.01 −7.8 ± 9
12,13-DiHODE t0 0.39 ± 0.05 0.12 ± 0.03
t12 0.33 ± 0.03 −5.1 ± 5.1 0.11 ± 0.01 −4.7 ± 9.3
15,16-DiHODE t0 7.95 ± 0.52 8.39 ± 1.50
t12 5.01 ± 0.36 −33.7 ± 7.4 0.003 7.51 ± 0.58 −11.5 ± 12.8
EPA-derived oxylipins Hydroxy FA 5-HEPE t0 7.14 ± 0.78 0.17 ± 0.03
t12 14.7 ± 3.48 115 ± 40.5 0.048 0.23 ± 0.02 26.4 ± 12.8
8-HEPE t0 6.59 ± 0.75 0.19 ± 0.02
t12 16.0 ± 4.35 149 ± 49.8 0.049 0.32 ± 0.02 46.4 ± 10.1 0.01
12-HEPE t0 11.3 ± 1.40 ≤ LOQ
t12 30.0 ± 9.20 172 ± 60.3 ≤ LOQ
15-HEPE t0 8.65 ± 1.03 0.43 ± 0.06
t12 23.1 ± 6.71 176 ± 59.7 0.64 ± 0.06 32.9 ± 9.2 0.019
Epoxy FA 8(9)-EpETE t0 2.31 ± 0.34 ≤ LOQ
t12 4.86 ± 1.01 154 ± 76.4 0.019 ≤ LOQ
11(12)-EpETE t0 2.87 ± 0.32 ≤ LOQ
t12 5.19 ± 0.81 102 ± 44.6 0.007 ≤ LOQ
14(15)-EpETE t0 2.42 ± 0.27 ≤ LOQ
t12 4.97 ± 0.93 140 ± 67.3 0.016 ≤ LOQ
17(18)-EpETE t0 3.06 ± 0.29 0.11 ± 0.02
t12 6.59 ± 1.38 124 ± 46.9 0.019 0.20 ± 0.03 78.7 ± 37.0 0.038
Dihydroxy FA 11,12-DiHETE t0 0.34 ± 0.04 0.05 ± 0.01
t12 0.57 ± 0.05 83.0 ± 23.2 0.001 0.13 ± 0.02 132 ± 37.0 0.006
14,15-DiHETE t0 0.27 ± 0.05 0.68 ± 0.16
t12 0.43 ± 0.04 87.0 ± 27.5 0.005 LOQ
17,18-DiHETE t0 0.61 ± 0.07 0.64 ± 0.12
t12 1.00 ± 0.15 68.9 ± 20.3 0.011 1.58 ± 0.23 123 ± 29.1 0.012
DHA-derived Epoxy FA 10(11)-EpDPE t0 4.41 ± 0.44 1.84 ± 0.36
t12 4.77 ± 0.52 14.4 ± 12.7 2.43 ± 0.40 17.9 ± 21.6
13(14)-EpDPE t0 2.89 ± 0.28 0.24 ± 0.05
t12 3.10 ± 0.46 19.8 ± 23.4 0.30 ± 0.05 48.5 ± 30.6
16(17)-EpDPE t0 3.08 ± 0.33 0.12 ± 0.02
t12 3.31 ± 0.57 19.9 ± 21.9 0.17 ± 0.04 15.0 ± 31.1
19(20)-EpDPE t0 4.64 ± 0.45 0.33 ± 0.06
t12 5.12 ± 1.05 19.8 ± 23.9 0.39 ± 0.06 15.9 ± 26.7
Dihydroxy FA 4,5-DiHDPE t0 3.74 ± 0.35 0.24 ± 0.05
t12 3.98 ± 0.47 9.4 ± 12.6 0.33 ± 0.05 44.9 ± 40.4
7,8-DiHDPE t0 1.95 ± 0.22 0.12 ± 0.02
t12 1.73 ± 0.24 −2.2 ± 14.5 0.16 ± 0.02 20.8 ± 13.2
10,11-DiHDPE t0 0.72 ± 0.08 0.21 ± 0.04
t12 0.62 ± 0.09 −7.4 ± 14.0 0.27 ± 0.02 23.2 ± 12.0
13,14-DiHDPE t0 0.37 ± 0.03 0.20 ± 0.03
t12 0.33 ± 0.04 −6.7 ± 13.7 0.26 ± 0.03 14.7 ± 6.9
16,17-DiHDPE t0 0.73 ± 0.06 0.38 ± 0.06
t12 0.78 ± 0.11 18.4 ± 23.1 0.54 ± 0.07 25.4 ± 16.1
19,20-DiHDPE t0 2.79 ± 0.29 2.58 ± 0.38
t12 2.14 ± 0.25 −19.9 ± 9.7 0.043 3.59 ± 0.39 21.5 ± 13.4

≤LOQ, below limit of quantification